Autolus Therapeutics plc (NASDAQ:AUTL) is Syncona Portfolio Ltd’s Largest Position

Syncona Portfolio Ltd reduced its position in Autolus Therapeutics plc (NASDAQ:AUTL) by 10.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,640,720 shares of the company’s stock after selling 1,913,904 shares during the quarter. Autolus Therapeutics makes up about 73.8% of Syncona Portfolio Ltd’s holdings, making the stock its largest position. Syncona Portfolio Ltd owned about 6.25% of Autolus Therapeutics worth $39,106,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Hennion & Walsh Asset Management Inc. purchased a new stake in Autolus Therapeutics in the fourth quarter worth $611,000. Wellington Management Group LLP increased its position in Autolus Therapeutics by 35.4% in the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock worth $87,919,000 after buying an additional 6,330,392 shares during the last quarter. FMR LLC increased its position in Autolus Therapeutics by 44.6% in the third quarter. FMR LLC now owns 17,773,873 shares of the company’s stock worth $64,519,000 after buying an additional 5,478,706 shares during the last quarter. Erste Asset Management GmbH purchased a new position in shares of Autolus Therapeutics in the third quarter valued at $708,000. Finally, GSA Capital Partners LLP purchased a new position in shares of Autolus Therapeutics in the third quarter valued at $1,082,000. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Stock Up 12.6 %

Autolus Therapeutics stock opened at $2.06 on Thursday. Autolus Therapeutics plc has a 52 week low of $1.68 and a 52 week high of $6.63. The business has a 50-day simple moving average of $2.15 and a 200 day simple moving average of $3.09. The stock has a market cap of $548.15 million, a price-to-earnings ratio of -1.70 and a beta of 2.07.

Analyst Ratings Changes

AUTL has been the subject of several recent research reports. The Goldman Sachs Group upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $7.00 to $7.60 in a research report on Monday, November 18th. Redburn Atlantic upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a research report on Friday, November 15th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday, January 13th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $10.40.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.